The only LTP with an evidence-based switch protocol1*

This protocol was prospectively studied in the OASISplus clinical trial, which considered time to pharmacologic effect.1

The 14-day protocol used to switch to DAWNZERA1

Prior lanadelumab

  1. Step 1 in the DAWNZERA switch protocol.

    Stop taking lanadelumab

  2. Step 2 in the DAWNZERA switch protocol.

    Wait 14 days before starting DAWNZERA

Prior berotralstat or C1-INH

  1. Step 1 in the DAWNZERA switch protocol.

    Start DAWNZERA

  2. Step 2 in the DAWNZERA switch protocol.

    Continue taking the current dose of berotralstat or the C1-INH for 14 days

C1-INH=C1-inhibitor; LTP=long-term prophylactic treatment.

*Switch protocol used in the OASISplus study.1

See other areas to explore:

View switch data Get patients started

IMPORTANT SAFETY INFORMATION & INDICATION

CONTRAINDICATIONS

DAWNZERA is contraindicated in patients with a history of serious hypersensitivity reactions, including anaphylaxis, to donidalorsen or any of the excipients in DAWNZERA.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions, including anaphylaxis, have been reported in patients treated with DAWNZERA. If signs and symptoms of serious hypersensitivity reactions occur, discontinue DAWNZERA and institute appropriate therapy.

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥ 5%) are injection site reactions, upper respiratory tract infection, urinary tract infection, and abdominal discomfort.

INDICATION

DAWNZERA (donidalorsen) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.

Please see full Prescribing Information for DAWNZERA.

Reference: 1. Riedl MA, Bernstein JA, Jacobs JS, et al. Donidalorsen treatment of hereditary angioedema in patients previously on long-term prophylaxis. J Allergy Clin Immunol Pract. 2025;13(9):2381-2389.e3. doi:10.1016/j.jaip.2025.06.018